WO2008125116A3 - Inhibition de l'u-par - Google Patents

Inhibition de l'u-par Download PDF

Info

Publication number
WO2008125116A3
WO2008125116A3 PCT/DK2008/050075 DK2008050075W WO2008125116A3 WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3 DK 2008050075 W DK2008050075 W DK 2008050075W WO 2008125116 A3 WO2008125116 A3 WO 2008125116A3
Authority
WO
WIPO (PCT)
Prior art keywords
aptamers
present
prevention
proteolytic activity
relates
Prior art date
Application number
PCT/DK2008/050075
Other languages
English (en)
Other versions
WO2008125116A2 (fr
Inventor
Joergen Kjems
Daniel Miotto Dupont
Peter A Andreasen
Original Assignee
Univ Aarhus
Joergen Kjems
Daniel Miotto Dupont
Peter A Andreasen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aarhus, Joergen Kjems, Daniel Miotto Dupont, Peter A Andreasen filed Critical Univ Aarhus
Publication of WO2008125116A2 publication Critical patent/WO2008125116A2/fr
Publication of WO2008125116A3 publication Critical patent/WO2008125116A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des aptamères capables de se lier à une forme de la protéine activatrice du plasminogène de type urokinase, u-PA, se liant à un récepteur. D'autre part, la présente invention concerne l'utilisation des aptamères pour la prévention de l'activité protéolytique favorisée par l'u-PA à la surface cellulaire afin de préparer une composition destinée à prévenir, ou à contrer, l'activité protéolytique à la surface d'une cellule. Les aptamères de la présente invention peuvent de plus être utilisés comme agents d'imagerie ou utilisés pour le traitement ou la prévention du cancer et/ou de la dissémination métastatique. La présente invention concerne également des compositions pharmaceutiques et des kits de diagnostic comprenant des aptamères.
PCT/DK2008/050075 2007-03-31 2008-03-28 Inhibition de l'u-par WO2008125116A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200700506 2007-03-31
DKPA200700506 2007-03-31
DKPA200701559 2007-11-01
DKPA200701559 2007-11-01

Publications (2)

Publication Number Publication Date
WO2008125116A2 WO2008125116A2 (fr) 2008-10-23
WO2008125116A3 true WO2008125116A3 (fr) 2009-03-12

Family

ID=39864405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2008/050075 WO2008125116A2 (fr) 2007-03-31 2008-03-28 Inhibition de l'u-par

Country Status (1)

Country Link
WO (1) WO2008125116A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011341018A1 (en) * 2010-12-10 2013-07-25 Merck Patent Gmbh Aptamer labeled with F-19 nucleus for targeted molecular imaging by MRI
HUE048574T2 (hu) 2012-07-12 2020-08-28 Hangzhou Dac Biotech Co Ltd Sejthez kötõdõ molekulák citotoxikus szerekkel képzett konjugátumai
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
CA2991973C (fr) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Lieurs de pontage pour la conjugaison d'une molecule de liaison cellulaire
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN106497919A (zh) 2016-11-02 2017-03-15 四川大学 一种核酸适配体as1411修饰的dna四面体及其制备方法
KR20220150408A (ko) 2016-11-14 2022-11-10 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2019165105A1 (fr) * 2018-02-26 2019-08-29 The Board Of Trustees Of The Leland Stanford Junior University Ligands du récepteur d'urokinase et leur utilisation dans le traitement, le dépistage et l'imagerie du cancer
AU2019452577B2 (en) 2019-06-29 2023-08-24 Hangzhou Dac Biotech Co., Ltd. Cell-binding molecule-Tubulysin derivative conjugate and preparation method therefor
CN111453729B (zh) * 2019-08-26 2021-06-18 山东大学 一种超声波辅助制备超级活性炭的方法及其应用
EP4194555A1 (fr) * 2021-12-09 2023-06-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Aptamères d'adn inhibant la liaison d'activateur du plasminogène de type urokinase (upa) avec un récepteur d'activateur de plasminogène de type urokinase (upar) et l'activité upa

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
HAMULA C.L.A. ET AL.: "Selection and analytical applications of Aptamers", TRENDS IN ANALYTICAL CHEMISTRY, vol. 25, no. 7, 2006, pages 681 - 691, XP002509244 *
JAYASENA S.D.: "Aptamers: an emerging class of molecules that rival antibodies in diagnostics", CLINICAL CHEMISTRY, vol. 45, no. 9, 1999, pages 1628 - 1650, XP002509245 *
SCHMITT M. ET AL.: "The Urokinase Plasminogen Activator system as a novel target for tumour therapy", FIBRINOLYSIS & PROTEOLYSIS, vol. 14, no. 2/3, 2000, pages 114 - 132, XP002509198 *
SCHWEINITZ A. ET AL.: "Design of novel and selective inhibitors of urokinase-type Plasminogen Activator with improved pharmakokinetic properties for use as antimetastatic agents", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 32, 6 August 2004 (2004-08-06), pages 33613 - 33622, XP002509197 *
SKRYPINA N.A. ET AL.: "In vitro selection of single-stranded DNA aptamers that bind human pro-urokinase", NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS, vol. 23, no. 6-7, October 2004 (2004-10-01), pages 891 - 893, XP008100024 *
ULRICH H.: "DNA and RNA Aptamers as modulators of protein function", MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS LTD, BUSSUM, NL, vol. 1, no. 2, 1 March 2005 (2005-03-01), pages 199 - 208, XP001248936, ISSN: 1573-4064 *
ULRICH H.: "RNA Aptamers: from basic science towards therapy", HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, vol. 173, 2006, pages 305 - 326, XP001249105 *

Also Published As

Publication number Publication date
WO2008125116A2 (fr) 2008-10-23

Similar Documents

Publication Publication Date Title
WO2008125116A3 (fr) Inhibition de l'u-par
EP1859793A4 (fr) Nouvelle utilisation combinee d'un compose de sulfonamide
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
WO2008028965A3 (fr) Inhibiteurs de la protéine phosphatase 1, de gadd34 et du complexe protéine phosphatase 1/gadd34, leur préparation et leurs applications
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
MY143795A (en) Tetrahydropyridoindole derivatives
CL2011001863A1 (es) Compuestos derivados de fenilaminopirimidinas, inhibidores de quinasa del linfoma anaplastico; composicion farmaceutica; combinacion farmacologica; y su uso en el tratamiento de trastornos proliferativos tales como linfoma, osteosarcoma, melanoma o tumor de mama, renal y de prostata, entre otros (divisional solicitud 3552-07).
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
IL228952B (en) Use of preparations containing iron citrate to prepare drugs to reduce serum phosphate levels
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
WO2009031106A3 (fr) Utilisation d'une combinaison d'hespéridine et d'un micro-organisme pour influer sur la fonction de barrière de la peau
WO2008030883A3 (fr) Traitement du cancer
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2009114725A3 (fr) Mobilisation de cellules souches hématopoïétiques
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2006113483A3 (fr) Methodes et compositions pour le traitement ou la prevention du cancer
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
WO2005099749A3 (fr) Methodes pour controler une angiogenese et une proliferation cellulaire
WO2008042480A3 (fr) Inhibiteurs époxyde de cystéine protéases
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
WO2007010394A3 (fr) Inhibition du potentiel tumorigene de cellules souches tumorales par lif (facteur inhibiteur de la leucemie) et bmps (proteines morphogenetiques osseuses)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715629

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08715629

Country of ref document: EP

Kind code of ref document: A2